BRIEF-AstraZeneca Says Imfinzi Improved OS & PFS In Limited-Stage SCLC

AstraZeneca PLC: * IMFINZI IMPROVED OS & PFS IN LIMITED-STAGE SCLC

* IMFINZI IMPROVED SURVIVAL & PROGRESSION-FREE SURVIVAL FOR PATIENTS WITH LIMITED-STAGE SMALL CELL LUNG CANCER IN ADRIATIC PHASE III TRIAL * SAFETY PROFILE FOR IMFINZI WAS CONSISTENT WITH ITS KNOWN PROFILE, AND NO NEW SAFETY SIGNALS WERE IDENTIFIED. Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)